CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy | Signal-Averaged Electrocardiography (SAECG)

Defines Blue Cross Blue Shield - Rhode Island coverage stance for signal-averaged electrocardiography (SAECG) for Commercial and Medicare (BlueCHiP) members, including coding and clinical rationale.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySignal-Averaged Electrocardiography (SAECG) coverage policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateDec 2, 2001

Next Review DateN/A

Key ActionVerify member benefits and refer to the Evidence of Coverage, Subscriber Agreement, or Benefit Booklet for member-specific coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1CPT code listed as not medically necessary

2Products listed as not covered

0Prior authorization required

2001Policy effective year

Coverage Determination

Not Medically Necessary / Not Covered

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySignal-Averaged Electrocardiography (SAECG) coverage policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateDec 2, 2001

Next Review DateN/A

Key ActionVerify member benefits and refer to the Evidence of Coverage, Subscriber Agreement, or Benefit Booklet for member-specific coverage.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Billing Notes

Prior Authorization

Prior authorization is not required for this service.

Billing Rule

Provider Billing Action

Provider action: Document medical necessity and inform members if services are non-covered. Follow applicable billing rules and submit accurate coding for claims.

Documentation Required

Verify Benefits and Member Documents

Verify member benefits and coverage before providing services. Refer to the member's Evidence of Coverage, Subscriber Agreement, or Benefit Booklet for coverage details and confirmation of not medically necessary determinations.

Denial Risk

Denial Risk for SAECG

Denial risk: Signal‑averaged electrocardiography (SAECG) (CPT 93278) is not covered / not medically necessary for BlueCHiP for Medicare and Commercial products and claims may be denied.

CPT 93278 — Signal‑averaged electrocardiography (SAECG), with or without ECG

Clinical Background

Signal-averaged electrocardiography (SAECG) is a computerized analysis of ECG signals used to detect ventricular late potentials (VLPs). VLPs are small, delayed electrical signals thought to arise from viable cardiac muscle bordering an infarcted area and represent asynchronous conduction that may predispose to ventricular tachyarrhythmias. SAECG has been studied as one of several risk markers — alongside left ventricular ejection fraction, Holter monitoring, electrophysiologic studies, and T-wave alternans — to identify patients at increased risk of arrhythmic events and sudden cardiac death.

Key Definitions

Ventricular late potentials (VLPs) — definition and clinical significance

DefinitionVentricular late potentials (VLPs) are small, delayed electrical signals detected on signal-averaged electrocardiography representing aberrant, asynchronous impulses arising from viable isolated cardiac muscle bordering an infarcted area.

Clinical significanceVLPs are thought to reflect areas of slow conduction that may predispose to ventricular tachyarrhythmias and sudden cardiac death, and have been investigated as a risk factor for arrhythmic events after myocardial infarction and in cardiomyopathy.

Role in risk stratificationSAECG–detected VLPs have been studied alongside other risk markers (e.g., LVEF, Holter monitoring, electrophysiologic studies, T-wave alternans) to identify patients at higher risk for ventricular arrhythmias for potential primary or secondary prevention interventions (drugs or ICDs).

Measurement methodVLPs are identified using SAECG, a computerized analysis of small segments of a standard ECG to reveal signals otherwise obscured by background skeletal muscle activity.

Implication for treatment decisionsPresence of VLPs has been used to inform consideration of antiarrhythmic therapy or implantable cardiac defibrillator placement in patients assessed as high risk for ventricular arrhythmias.

OpenPayer

Medical Coverage Policy | Signal-Averaged Electrocardiography (SAECG)

Coverage Determination

Billing and Coding

Provider Actions and Billing Notes

Clinical Background

Key Definitions